Omalizumab
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Drug Allergy
Conditions
Drug Allergy
Trial Timeline
Jul 1, 2014 → Dec 1, 2017
NCT ID
NCT02118987About Omalizumab
Omalizumab is a phase 1 stage product being developed by Novartis for Drug Allergy. The current trial status is completed. This product is registered under clinical trial identifier NCT02118987. Target conditions include Drug Allergy.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (18)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05424523 | Pre-clinical | Completed |
| NCT05157087 | Pre-clinical | Completed |
| NCT04037176 | Approved | Completed |
| NCT02550106 | Approved | Completed |
| NCT02329223 | Phase 3 | Completed |
| NCT02262130 | Phase 2 | Completed |
| NCT02118987 | Phase 1 | Completed |
| NCT02023151 | Approved | Completed |
| NCT01328886 | Phase 3 | Completed |
| NCT01155700 | Phase 3 | Completed |
| NCT00500539 | Phase 3 | Completed |
| NCT00264849 | Approved | Completed |
| NCT00180011 | Phase 2/3 | Completed |
| NCT00639691 | Approved | Completed |
| NCT00226200 | Pre-clinical | Terminated |
| NCT00482248 | Phase 3 | Completed |
| NCT00482508 | Phase 3 | Completed |
| NCT00046748 | Phase 3 | Completed |
Competing Products
20 competing products in Drug Allergy